Navigation Links
Takeda Responds to Verdict in Diabetes Drug Case
Date:4/26/2013

DEERFIELD, Ill., April 26, 2013 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Jack Cooper et al. v. Takeda Pharmaceuticals America, Inc., et al., No. CGC-12-518535 the jury found in favor of the plaintiffs and awarded a total of $6.5 million in damages. Takeda has filed motions asking the judge to rule in favor of the company as a matter of law and is considering its options, including a possible appeal if the motions are denied. The trial began on February 19 in Los Angeles before Judge Kenneth R. Freeman .

"Takeda respectfully disagrees with the jury's verdict," said Kenneth D. Greisman , senior vice president, general counsel and secretary, Takeda Pharmaceuticals U.S.A., Inc. "Takeda empathizes with patients like Mr. Cooper, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer.  We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS. We promptly disclosed ACTOS safety data to the U.S. Food & Drug Administration and other regulatory authorities and provided updated product information to health care professionals and patients."

The company is confident in the therapeutic benefits of ACTOS (pioglitazone HCl) and its importance as a treatment for type 2 diabetes.

"Patient safety is a critical priority for Takeda," said Greisman. "We plan to vigorously defend the company against future lawsuits."

Indication for ACTOS
ACTOS (pioglitazone) is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for the treatment of type 1 "juvenile" diabetes or diabetic ketoacidosis (increased ketones in blood or urine).

Important Safety Informati
'/>"/>

SOURCE Takeda Pharmaceuticals U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Launches New Subsidiary in Ecuador
2. Takeda lanza nueva subsidiaria en Ecuador
3. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
4. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
5. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
6. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
7. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
8. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
9. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
10. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
11. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Investor-Edge has initiated coverage ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow ...
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ready ... trackers for themselves and their kids, according to the ... Health & Fitness Go Mobile for Moms, the latest ... BabyCenter, the number 1 pregnancy and parenting web and ... 55 percent of moms surveyed say they can,t think ...
(Date:10/22/2014)... 2014  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that ... Officer, has been elected to the Company,s Board of ... G. Anderson , Executive Chairman of CryoLife, stated, "Since joining ... an excellent leader who is well positioned to maximize ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3
... Data presented yesterday showed that USL255, a novel ... less fluctuation in topiramate plasma levels than immediate-release ... These and other findings from the USL255 early ... the 64th annual American Epilepsy Society (AES) meeting ...
... Dec. 6, 2010 The Novartis Pharmaceutical Corporation ... disease control and tumor reduction in extensively pretreated ... become refractory after an autologous stem cell transplant, ... clinical trial presented today(1). In this ...
Cached Medicine Technology:Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 2Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 3Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... and length may be showing a genetic propensity for obesity ... genes have been linked to increased body fat, but the ... lean muscle, the researchers said. At 1 year, kids ... 2 and 3, however, these genes were linked to excessive ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts ... facts, figures and forecasts on the global medical markets. ... categories the Worldwide Medical Market Forecasts to 2019 ... on the worldwide medical market to reveal key insights ... data for 2010-2019, covering each country market individually, allowing ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... ... in the U.S., reNEW MAN (renewman.com) is promoting its national network of physicians to ... the company helps connect professional men that exhibit signs of low testosterone with a ... , ...
... , SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination ... progestin, increases a woman,s risk for dying from lung cancer, ... an analysis of data from the Women,s Health Initiative trial ... United States who had been randomly assigned to take either ...
... ... extensive collection of lift chairs and other mobility products. , ... Raleigh, NC (PRWEB) September 19, 2009 -- Lift Chairs 101, a leader in ... lifts , offering a variety of styles and prices in order to better meet the mobility ...
... , LOS ANGELES, Sept. 18 Advocates for seniors ... response to statements he made in an LA Times story that ran ... , "As the Governor stepped in to stop eviction notices ... preparing to send out similar notices to an estimated 140,000 seniors and ...
... , MISSION VIEJO, Calif., Sept. 18 ... company of the Ensign(TM) group of skilled nursing, rehabilitative care services ... has declared a quarterly cash dividend of $0.045 per share of ... shareholders of record as of September 30, 2009. Ensign has been ...
... , , , , ... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Wells, 57, has embarked on his third annual "Grandpa,s Road Trip" ... machine, the NxStage System One provides Mr. Wells the opportunity to ...
Cached Medicine News:Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 2Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 3Health News:Find a Local Andropause Doctor to Treat Low Testosterone with reNEW MAN 4Health News:Hormone Therapy May Make Lung Cancer More Likely 2Health News:Lift Chairs 101 Introduces New Bathtub Lift Line 2Health News:Disability Advocates Call-Out Governor Schwarzenegger for Honoring Mother-In-Law While Cutting Vital Services 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3
Angled, 7.5 mm tying platforms.,Titanium, 111 mm long, 6 mm tying platforms....
Hatsis tying forceps, titanium, long thin tying platforms....
Gills Colibri forceps, very fine pointed tips....
Fine tying forceps, curved tips, wide handle....
Medicine Products: